
-
Cytokinetics Inc NasdaqGS:CYTK Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Location: 350 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.cytokinetics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.674B
Cash
938.2M
Avg Qtr Burn
-99.5M
Short % of Float
12.19%
Insider Ownership
0.77%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aficamten Details Obstructive hypertrophic cardiomyopathy (oHCM) | PDUFA Approval decision | |
Aficamten Details Hypertrophic cardiomyopathies | Phase 3 Data readout | |
Aficamten Details Hypertrophic cardiomyopathies | Phase 3 Data readout | |
Omecamtiv Mecarbil (cardiac myosin activator) Details Pancreatic cancer, Heart disease, Heart failure | Phase 3 Data readout | |
Aficamten Details Hypertrophic cardiomyopathies | Phase 3 Update | |
CK-4021586 (CK-586) (cardiac myosin inhibitor) Details Heart disease, Heart failure | Phase 2 Data readout | |
CK-4015089 (CK-089) Details Muscular dystrophy | Phase 1 Data readout | |
CK-3828136(CK-136) (cardiac troponin activator) Details Heart failure, Heart disease, Epilepsy | Phase 1 Data readout | |
Reldesemtiv (CK-601) (next-generation fast skeletal muscle troponin activator (FSTA)) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Failed Discontinued |